Mark Cuban readies to fight Humira's megablockbuster franchise next month

Zachary Brennan

Senior Editor

Mark Cuban’s Cost Plus Drugs Company said today that it’s to compete with AbbVie’s multi-billion-dollar Humira franchise by entering the biosimilar fray alongside more than …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mark Cuban readies to fight Humira's megablockbuster franchise next month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mark Cuban read­ies to fight Hu­mi­ra's megablock­buster fran­chise next month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

For­mer FDA chief calls job cuts ‘hap­haz­ard, poor­ly thought-out’

NIH pay­ment cuts are 'rea­soned and ra­tio­nal,' gov­ern­ment says

No­vo looks to re­coup $830M from hy­per­ten­sion drug part­ner, claim­ing fraud

Af­ter re­search piv­ot, Bio­gen beefs up pipeline with Stoke's late-stage Dravet can­di­date

As part of turn­around, Sol­id Bio re­ports promis­ing ini­tial da­ta for Duchenne gene ther­a­py

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Mark Cuban readies to fight Humira's megablockbuster franchise next month

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence